DUPIXENT IS THE FIRST BIOLOGIC APPROVED IN CRSwNP THAT TARGETS THE INFLAMMATION UNDERLYING THE DISEASE—SO YOUR PATIENTS CAN ACHIEVE AND MAINTAIN CONTROL
aAt Week 52 (SINUS‑52: other secondary endpoint) with DUPIXENT 300 mg Q2W + INCS (n=150) (9.53 from a baseline score of 13.46) vs 6% worsening with placebo + INCS (n=153) (-0.77 from a baseline score of 13.78) (LSM difference: 10.30 [95% CI: 8.50, 12.10]). Analysis of this endpoint was not multiplicity controlled; results are descriptive.3,4
bAt Week 24 (SINUS‑24: coprimary endpoint) with DUPIXENT Q2W + INCS (n=143) (-1.34 from a baseline score of 2.26) vs 18% improvement with placebo + INCS (n=133) (-0.45 from a baseline score of 2.45) (LSM difference: -0.89 [95% CI: -1.07, -0.71]).1
cIndividually, SCS reduction and need for sino-nasal surgery were not multiplicity-adjusted endpoints.
INCS, intranasal corticosteroid; LSM, least squares mean; Q2W, once every 2 weeks; SCS, systemic corticosteroid; UPSIT, University of Pennsylvania Smell Identification Test.
Unique Mechanism of Action (MOA)
DUPIXENT is a dual inhibitor of
Multiple Administration Options
Work with your patients to decide how to administer DUPIXENT: either administer at home or administer in the office.1
See Dosing and AdministrationA patient or caregiver may inject DUPIXENT after training in subcutaneous injection technique.
Safety Data
View safety data across clinical trials.
Pen is
available for patients
18+ years!
Support can make all the difference. DUPIXENT MyWay® is a patient support program that can help enable access to DUPIXENT and offers financial assistance for eligible patients, one-on-one nursing support, and more.
Check Formulary Status in Your Area
See the coverage status for DUPIXENT, prior authorization, and step edit information by ZIP code.